Aubrey introduces new TSA-friendly sized lotions
TAMPA, Fla. — Natural skin care brand Aubrey, which is sold at natural food stores, has introduced new travel-sized moisturizing lotions for those on the go.
As with its entire range of personal care products, Aubrey packs its lotions with herbals and plant extracts in their most natural form, and no synthetic additives or petrochemicals of any kind, the company said. The travel size collection includes Evening Primrose, Collagen and Almond, Sea Buckthorn, unscented, Rosa Mosqueta and Honeysuckle-CoQ10.
The lotions are priced at $6.49 each.
NRF awards law enforcement, loss prevention professionals for aiding fight against retail crime
NEW ORLEANS — During its annual Loss Prevention Conference and Expo, the National Retail Federation honored six individuals that exhibited exemplary dedication and investigative skills in solving retail crimes.
NRF gave out its Law Enforcement Retail Partnership Award to the following people:
Kebharu Smith, assistant U.S. attorney, Department of Justice – Houston office;
Armando Astorga, group supervisor of Immigration Customs Enforcement (ICE) – Homeland Security Investigations;
Juan Pagan, special agent, ICE – Homeland Security Investigations;
Terry Muise, special agent, ICE – Homeland Security Investigations;
Matt Wood, special agent, ICE – Homeland Security Investigations; and
Georgina Cervantes, intelligence research analyst, ICE – Homeland Security Investigations.
The NRF said those awarded were involved in an investigation of organized retail crime in Houston back in July 2009, which targeted CVS/pharmacy and Walgreens stores in the area. Working together, organized retail crime investigators were able to conduct a joint surveillance operation with Immigration Customs Enforcement — part of Homeland Security Investigations — which uncovered a high-level fence operation based in Houston. The operation was led by a person who aggressively recruited and paid illegal immigrants to travel to pharmacies throughout the continental U.S. and steal over-the-counter medications and health and beauty products. Over the course of the investigation, federal agents and investigators found approximately $20 million worth of stolen retail merchandise had been illicitly purchased and sold, and more than 75 suspects were identified and linked to the operation.
FDA declines to approve new clinical indication for Xarelto
RARITAN, N.J. — The Food and Drug Administration has issued a complete response letter regarding a supplemental new drug application for a medication developed by Janssen Research and Development.
Janssen confirmed the receipt of the CRL for Xarelto (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome. The drug maker submitted this sNDA in December 2011 and received a priority review designation from the FDA on Feb. 27. On May 23, the FDA’s Cardiovascular and Renal Drugs Advisory Committee narrowly voted against recommending approval of Xarelto in this indication.
The drug currently is approved for three clinical uses: to reduce the risk of blood clots in the legs and lungs of people who have just had knee replacement surgery; to reduce this risk in people who have just had hip replacement surgery; and to reduce the risk of both hemorrhagic and thrombotic strokes, as well as other blood clots in people with atrial fibrillation not caused by a heart valve problem.
Janssen is evaluating the CRL and will respond to the agency’s questions.